Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232765 · ClinicalTrials.gov registry record · Phase 3
Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)
A Phase 3 study of Coronary Artery Disease, sponsored by Cordis US.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,058
- Enrollment target
- 1
- Study location
NCT00232765: Completed Phase 3 study of Coronary Artery Disease, sponsored by Cordis US.
NCT00232765 is a Phase 3 study of Coronary Artery Disease that has completed, run by Cordis US. The registered enrollment target is 1,058 participants, below the 1,282-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232765, a Phase 3 study of Coronary Artery Disease, has completed, sponsored by Cordis US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,058 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITYTM stent in reducing target vessel failure in de novo native coronary artery lesions as compared to the uncoated Bx VELOCITYTM balloon-expandable stent. Both stents are mounted on the Raptorâ over-the-wire (OTW) Stent Delivery System.
Conditions Studied
Interventions
- DEVICE CYPHER Sirolimus-Eluting Stent
- DEVICE Uncoated BX VELOCITY Balloon-Expandable Stent
Study Locations (1)
New York
- New York Presbyterian Hospital/Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,058 participants |
| Start Date | 2001-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
What the finished NCT00232765 record still lists
NCT00232765 is an interventional study that assigns participants to a tested intervention. Its 1,058 participants enrollment target places it among the larger protocols in the corpus, below the 1,282-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which CYPHER Sirolimus-Eluting Stent is the first listed.
NCT00232765 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00232765 about?
NCT00232765 is a clinical study titled "Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)". The main objective of this study is to assess the safety and effectiveness of the sirolimus-coated Bx VELOCITYTM stent in reducing target vessel failure in de novo native coronary artery lesions as compared to the uncoated Bx VELOCITYTM balloon-expandable stent. Both stents are mounted on the Raptor...
What is the current status of trial NCT00232765?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,058 participants. The study started on 2001-02. Estimated completion is 2008-11.
What conditions does trial NCT00232765 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00232765?
The interventions under investigation include: CYPHER Sirolimus-Eluting Stent (DEVICE), Uncoated BX VELOCITY Balloon-Expandable Stent (DEVICE).
Who is sponsoring clinical trial NCT00232765?
This trial is sponsored by Cordis US, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00232765 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00232765's enrollment target sits among peer trials
1,058 45th of 219 higher than 175 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
RECRUITING · Phase 3
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia